AL
XERS icon

Aspiriant LLC’s Xeris Biopharma Holdings XERS Stock Holding History

Aspiriant LLC’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Buy
20,030
+30
+0.2% +$192 ﹤0.01% 392
2026
Q1 		$116K Hold
20,000
– – ﹤0.01% 336
2025
Q4 		$157K Hold
20,000
– – ﹤0.01% 317
2025
Q3 		$163K Buy
+20,000
New +$133K 0.01% 295

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Aspiriant LLC's XERS Position: Q2 2026 in Review

Aspiriant LLC increased its Xeris Biopharma Holdings (XERS) stake by 0.15% in Q2 2026, buying an estimated $192 and bringing the position to 20,030 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #392.

Aspiriant LLC first reported a position in XERS in Q3 2025 and has held it in 4 quarters since. The position peaked at $163K in Q3 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Aspiriant LLC held 20,030 shares of Xeris Biopharma Holdings worth $159K as of Q2 2026.
  • Aspiriant LLC bought 30 Xeris Biopharma Holdings shares in Q2 2026, an estimated $192.
  • Xeris Biopharma Holdings made up ﹤0.01% of Aspiriant LLC's portfolio in Q2 2026, its #392 holding.
  • Aspiriant LLC first reported a position in Xeris Biopharma Holdings in Q3 2025 and has held it in 4 quarters since.
  • Aspiriant LLC's Xeris Biopharma Holdings position peaked at $163K in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Aspiriant LLC's 13F filing for Q2 2026, filed 20 Jul 2026.